The synergistic activity of the two BLIs in combination with FDC was investigated by DD test or Etest using disks of ceftazidime and ceftazidime-avibactam (Oxoid) containing 10 μg of ceftazidime and 4 μg of avibactam or strips of ampicillin and ampicillin-sulbactam (Liofilchem, Italy) containing 0.016 to 256 mg/L of ampicillin and 0.008 to 128 mg/L of sulbactam, placed on both FDC-free MHA plates and MHA plates containing 32 mg/L or 1 mg/L of FDC that had been previously inoculated with an FDC-nonsusceptible induced strain (FDC MIC of >32 mg/L) or strains with FDC MICs of >1 mg/L. A. baumannii ATCC 17978 was used as the activity control with 1 mg/L of FDC. The comparison between the inhibition obtained with ceftazidime and ceftazidime-avibactam or ampicillin and ampicillin-sulbactam in the plates with and without FDC allowed us to evaluate the efficacy of the BLIs.
Ceftazidime and ceftazidime avibactam
Manufactured by Thermo Fisher Scientific
Sourced in Italy
Ceftazidime and ceftazidime-avibactam are broad-spectrum antibacterial agents used for the treatment of various bacterial infections. Ceftazidime is a cephalosporin antibiotic, while ceftazidime-avibactam combines ceftazidime with the beta-lactamase inhibitor avibactam. These products are intended for use in clinical settings by healthcare professionals, in accordance with applicable regulations and guidelines.
Automatically generated - may contain errors
Lab products found in correlation
2 protocols using ceftazidime and ceftazidime avibactam
1
Synergistic Activity of BLIs and FDC
2
Synergistic Activity of BLIs and FDC
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
The synergistic activity of the two BLIs in combination with FDC was investigated by DD test or Etest using disks of ceftazidime and ceftazidime-avibactam (Oxoid) containing 10 μg of ceftazidime and 4 μg of avibactam or strips of ampicillin and ampicillin-sulbactam (Liofilchem, Italy) containing 0.016 to 256 mg/L of ampicillin and 0.008 to 128 mg/L of sulbactam, placed on both FDC-free MHA plates and MHA plates containing 32 mg/L or 1 mg/L of FDC that had been previously inoculated with an FDC-nonsusceptible induced strain (FDC MIC of >32 mg/L) or strains with FDC MICs of >1 mg/L. A. baumannii ATCC 17978 was used as the activity control with 1 mg/L of FDC. The comparison between the inhibition obtained with ceftazidime and ceftazidime-avibactam or ampicillin and ampicillin-sulbactam in the plates with and without FDC allowed us to evaluate the efficacy of the BLIs.
About PubCompare
Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.
We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.
However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.
Ready to get started?
Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required
Revolutionizing how scientists
search and build protocols!